Spots Global Cancer Trial Database for Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Phenoxodiol may help docetaxel work better by making tumor cells more sensitive to the drug. PURPOSE: This randomized phase I/II trial is studying the side effects of docetaxel when given together with either phenoxodiol or placebo and to see how well it works in treating patients with recurrent advanced ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.

Detailed Description: OBJECTIVES: Primary * Determine the safety and tolerability of combination therapy comprising phenoxodiol and docetaxel in patients with recurrent or persistent advanced ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer. Secondary * Determine the effect of phenoxodiol on the toxicity of docetaxel using a weekly treatment regimen. * Determine if combination therapy comprising phenoxodiol and docetaxel is more efficacious than docetaxel therapy alone. * Determine if combination therapy comprising phenoxodiol and docetaxel affects blood levels of either drug. * Determine phenotypic differences in the tumor cells of "responders" and "non-responders." OUTLINE: This is a randomized, placebo-controlled, double-blind study. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral placebo three times daily on days 1-21. * Arm II: Patients receive oral phenoxodiol three times daily on days 1-21 and docetaxel as in arm I. Treatment in both arms repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed monthly for 6 months, every 3 months for 1 year, and then annually thereafter. PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study. 3/31/2017 NOTE This study was terminated 10/2009 due to lack of enrollment. The study never progressed to Phase 2.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial